LLY compared with MLTX: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

MLTXMoonLake Immunotherapeutics

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

MLTXMoonLake Immunotherapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

MLTX2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±14.2%▼−1.20%×0.08

Q2 FY26±23.0%▼−5.09%×0.22

= impliedLLY realized, solidMLTX realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedspan: LLY 267d · MLTX 86dSource: market data

LLYELI Lilly & Co

1,369.58▲+0.36%

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

MLTXMoonLake Immunotherapeutics

11.31▲+4.71%

Regular sessionNov 6 '26

Mkt cap$919.2MRevenue—Revenue—

Compare

Regular sessionNov 6 '26

LLYELI Lilly & Co

MLTXMoonLake Immunotherapeutics

1,369.58▲+0.36%

Price

11.31▲+4.71%

$1.2T

Mkt cap

$919.2M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,369.58▲+0.36%vsMLTX11.31▲+4.71%Regular sessionNov 6 '26